Table 2.

Site-specific risk of cancers following a first primary MCC in the SEER Program (1986-2002)

Site of subsequent cancerAll subsequent cancers
Cancers occurring after 1 year*
No.SIR (95% CI)Median latency (y)No.SIR (95% CI)
Second cancers, all§1221.22 (1.01-1.45)2.4831.07 (0.85-1.33)
Solid tumors, all1011.13 (0.92-1.38)2.4711.03 (0.81-1.30)
Salivary gland311.55 (2.32-33.76)0.814.96 (0.06-27.62)
Stomach31.34 (0.27-3.93)2.421.16 (0.13-4.20)
Small intestine26.02 (0.68-21.73)1.913.87 (0.05-21.55)
Colon131.23 (0.66-2.11)3.9121.48 (0.76-2.58)
Rectum**30.88 (0.18-2.58)2.220.77 (0.09-2.77)
Other biliary††37.24 (1.46-21.16)3.339.34 (1.88-27.28)
Lung191.28 (0.77-2.01)2.3131.14 (0.61-1.95)
Skin, malignant melanoma41.45 (0.39-3.71)2.431.39 (0.28-4.07)
Female breast70.77 (0.31-1.58)2.560.83 (0.30-1.81)
Female genital tract61.67 (0.61-3.64)4.551.76 (0.57-4.12)
Male genital tract140.66 (0.36-1.10)1.170.43 (0.17-0.89)
Bladder71.11 (0.44-2.28)4.261.23 (0.45-2.69)
Kidney31.52 (0.31-4.44)1.121.15 (0.13-4.17)
Brain33.49 (0.70-10.19)1.923.01 (0.34-10.87)
Lymphohematopoietic, all141.70 (0.93-2.86)2.071.10 (0.44-2.27)
    NHL102.56 (1.23-4.71)2.051.65 (0.53-3.85)
    Multiple myeloma10.76 (0.01-4.25)5.910.99 (0.01-5.49)
    CLL32.72 (0.55-7.94)0.511.18 (0.02-6.56)
  • NOTE: Cancer sites presented in the table are those for which two or more subsequent cancers were observed after MCC (with the exception of multiple myeloma). Squamous and basal cell carcinomas of the skin are not reportable to the SEER Program, except for genital sites, and thus, are not included in the analyses.

  • * Risk excludes all cancers occurring within 1 year of a primary MCC diagnosis.

  • Risk excludes eight cancers occurring within 1 month of a first primary MCC diagnosis [lung (n = 3), Kaposi sarcoma (n = 1), NHL (n = 1), malignant melanoma (n = 1), small intestine (n = 1), and multiple myeloma (n = 1)].

  • Median time from diagnosis of first primary MCC to diagnosis of second cancer.

  • § Includes all malignant cancers except MCC. Includes five patients with third or higher order cancers [appendix (n = 1), brain (n = 1), breast (n = 1), prostate (n = 1), and colon (n = 1)].

  • P < 0.05.

  • Excludes lymphohematopoietic malignancies (n = 14) and tumors classified as miscellaneous (n = 7).

  • ** Numbers include rectum and rectosigmoid junction.

  • †† Includes all biliary sites other than liver and gallbladder.